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Summary Introduction: Chronic inflammation of the lung is a characteristic finding
in chronic obstructive pulmonary disease (COPD). Leptin is a pleiotropic cytokine
thought to play a role in host response to inflammation. As recent studies have shown
that leptin receptors are present in the lung, this study aimed to determine if leptin
is detectable in induced sputum of COPD patients and if there is a relationship
between leptin and other inflammatory markers in sputum.
Methods: Sputum was induced in 14 male patients with moderate COPD (FEV1: 56
(15) % pred.). Leptin, total tumour necrosis factor (TNF)-a, and C-reactive protein
(CRP) were analyzed in induced sputum supernatant by ELISA. Leptin was also
determined in EDTA plasma.
Results: Leptin was detectable in induced sputum of 10 COPD patients. A
significant relationship was found between sputum leptin and CRP (r ¼ 0:943;
Po0:001) and total TNF-a (r ¼ 0:690; Po0:01). Plasma leptin and sputum leptin
were inversely correlated (r ¼ 0:643; Po0:01).
Conclusion: The present study demonstrated that leptin is detectable in induced
sputum of patients with moderate COPD and is related to other inflammatory
markers. The observed correlations between leptin and inflammatory markers
in sputum may indicate that leptin is involved in the local inflammatory response
in COPD.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Leptin, initially discovered as a regulator of food
intake and energy expenditure, is increasingly
emerging as a pleiotropic cytokine. It is involved
in a variety of physiological and pathological
functions, including the regulation of hematopoi-
esis, angiogenesis, wound healing, and the immune
and inflammatory response (reviewed in Fantuzzi
and Faggioni1). The receptor for leptin (leptin-R)
has been demonstrated to be present throughout
the body, including the lung,2 which may suggest a
specific function of leptin in the lung.
Although the pathogenesis of chronic obstructive
pulmonary disease (COPD) is not clear, patients
with COPD have been shown to exhibit a chronic
inflammatory response in the airways. Elevated
numbers of alveolar macrophages and CD8þ Tcells
have been found in the peripheral airways and lung
parenchyma. In addition, an increased level of
neutrophils has been demonstrated in sputum and
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bronchoalveolar lavage (BAL) fluid of COPD pa-
tients. Furthermore, an increase in interleukin-8
(IL-8) and tumour necrosis factor-a (TNF-a), which
are assumed to act as chemo-attractants for
neutrophils, has been reported in sputum of COPD
patients (reviewed in Barnes 3).
In order to unravel the potential role of leptin in
this process of chronic inflammation, we wondered
if leptin is detectable in induced sputum of patients
with COPD and, if so, whether leptin is related to
other inflammatory markers in induced sputum of
these patients.
Materials and methods
The study population consisted of normal weight
male patients with clinically stable moderate to
severe COPD (GOLD II-III). Exclusion criteria were
regular use of inhaled steroids, a history of
respiratory disease other than COPD and a recent
exacerbation (4 weeks prior to inclusion). Forced
expiratory volume in 1 s (FEV1) was calculated from
the flow volume curve using a spirometer (Master-
lab, Jaeger, W .urzburg, Germany) applied before
and 15min after inhalation of a b2-agonist via a
metered-dose inhaler. FEV1 was expressed as a
percentage of reference values.4 Body composition
was estimated using single frequency (50 kHz) bio-
electrical impedance analysis (Xitron Technologies,
San Diego, CA, USA). Fat-free mass (FFM) was
calculated using the disease-specific equation
proposed by Schols and described by Steiner
et al.5 Fat mass (FM) was calculated by subtracting
FFM from weight. The ethical review board of
the University Hospital Maastricht approved the
study. All subjects have given a written informed
consent.
Sputum was induced through inhalation of 3%
hypertonic saline and processed with 0.1% dithio-
threitol (DTT; Sputolysin; Calbiochem, La Jolla, CA)
according to the procedure described by Keatings
et al.6 Blood was collected in evacuated blood
collecting tubes containing EDTA (Sherwood Medi-
cal, St. Louis, MO) in the morning before sputum
induction (8.00–12.00 am). Sputum and plasma
samples were stored at 801C until analysis.
Leptin was measured in induced sputum super-
natant and plasma by sandwich enzyme-linked
immunosorbent assay (ELISA).7 C-reactive protein
(CRP), total TNF-a (i.e. free TNF-a and TNF-a bound
to soluble TNF-receptors) were determined in
induced sputum supernatant by ELISA as de-
scribed.7,8 Lower detection limits were 120 pg/ml
for leptin, 100 pg/ml for CRP and 20 pg/ml for total
TNF-a. Presence of DTT resulted in less than 10%
inhibition of the detection of inflammatory media-
tors (data not shown).
Results are presented as mean7standard devia-
tion (SD) for normally distributed variables. Plasma
leptin levels were adjusted for FM when indicated.
Differences between the groups with detectable
and non-detectable leptin levels were analyzed
using the Mann–Whitney U-test. Correlations be-
tween parameters were calculated with Pearson’s
rank correlation analysis using SPSS (Statistical
Package for the Social Sciences, version 10.1 for
Windows, SPSS Inc., Chicago, IL, USA). Significance
was assessed at a P-value of 0.05.
Results
Fourteen weight-stable male patients with moder-
ate to severe COPD (FEV1: 56 (15) %pred., range:
26–76%pred) were included in this study. Baseline
characteristics are shown in Table 1. Mean smoking
history of the study population was 53 (range
25–125) pack years with 4 patients having quit
smoking for at least 1 year and 10 patients still
smoking. All patients tolerated the procedure of
sputum induction well and produced an adequate
specimen of sputum for analysis.
Table 2 shows the levels of inflammatory markers
with the correlations with sputum leptin. Leptin
was detectable in the sputum samples of 10 of the
14 patients, who did not differ from patients with
non-detectable leptin in lung function, but did have
a lower FM index (Table 3). The mean value of
leptin in sputum was 275 (1 3 5) pg/ml. In plasma,
leptin was detectable in all samples, with a mean
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Table 1 Clinical characteristics of the study
group.
n¼ 14 Mean SD
Age (yr) 59.9 8.3
Body mass index (kg/m2) 26.2 3.6
Fat-free mass index (kg/m2) 18.3 1.5
Fat mass (kg) 24.6 8.2
FEV1 (%pred) 56 15
FVC (%pred) 78 14
FEV1/ FVC 57 14
Smokers/ex-smokers 10/4
Smoking history (PY) 53 28
FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; SD: standard deviation; %pred: percentage
predicted; PY: pack years.
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level of 6915 (3681) pg/ml. After adjustment
for FM, which correlated positively with leptin
(r ¼ 0:719; P ¼ 0:008), mean plasma leptin level
was 290 (1 1 0) pg/ml/kg FM. Leptin in plasma and
in induced sputum were inversely correlated
(r ¼ 0:643; Po0:001), a correlation that was no
longer significant after plasma leptin had been
adjusted for FM. In induced sputum, leptin level
was strongly correlated with the acute phase
protein CRP (r ¼ 0:943; Po0:001: Fig. 1) and with
sputum TNF-a levels (r ¼ 0:690; P ¼ 0:006: Fig. 2).
No correlations were found between plasma
CRP and sputum leptin (r ¼ 0:274; P ¼ n:s:), plasma
CRP and plasma leptin (r ¼ 0:040; P¼ n:s:) or
between plasma CRP and sputum CRP (r ¼ 0:410;
P¼ n:s:). TNF-a was not detectable in plasma. In
sputum, CRP and TNF-a were positively correlated
(r ¼ 0:743; P ¼ 0:002). Sputum leptin, CRP and
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Table 2 Inflammatory mediators in sputum and plasma.
Mean SD Correlation with sputum leptin
Sputum
CRP (ng/ml) 1.1 0.9 0.943***
TNF-a (pg/ml) 53 27 0.690**
Leptin (pg/ml) 275 135 F
Plasma
CRP (ng/ml) 6.8 5.0 0.274
TNF-a ND F
Leptin (pg/ml) 6915 3681 0.643**
Leptin/FM (pg/ml/kg) 290 110 0.447
CRP¼C-reactive protein; TNF-a¼ tumour necrosis factor alpha; FM¼ fat mass; ND¼ not detectable; **Po0:010; ***Po0:001:
Table 3 Characteristics of patients with leptin level under detection limit compared to patients with detectable
leptin levels in sputum.
Sputum leptin level o120 pg/ml X120 pg/ml P-value
Mean (SD) Mean (SD)
n ¼ 4 n ¼ 10
Age (yr) 54.5 (11.6) 62.1 (6.0) n.s.
Body Mass Index (kg/m2) 28.6 (3.5) 25.1 (3.3) n.s.
Fat-Free Mass Index (kg/m2) 18.2 (0.5) 18.4 (1.9) n.s.
Fat mass Index (kg/m2) 10.4 (3.0) 7.1 (1.6) 0.031
FEV1 (%pred) 59 (10) 55 (17) n.s.
FVC (%pred) 86 (6) 75 (15) n.s.
FEV1/FVC 54 (13) 58 (16) n.s.
Smoking (PY) 41 (23) 58 (30) n.s.
Sputum CRP (ng/ml) 0.18 (0.10) 1.49 (0.70) 0.001
Sputum TNF-a (pg/ml) 30.4 (20.8) 61.9 (24.2) 0.048
Plasma Leptin (pg/ml) 10.8 (2.6) 5.3 (2.8) 0.014
Plasma Leptin/FM 0.36 (0.10) 0.26 (0.10) n.s.
SD: standard deviation; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; CRP: C-reactive protein: TNF-a:
tumour necrosis factor alpha; FM: fat mass; %pred: percentage predicted; PY: pack years.
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Figure 1 Correlation between leptin and CRP levels in
induced sputum (r ¼ 0:943; Po0:001).
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TNF-a were not related to smoking history, smoking
status or lung function (data not shown).
Discussion
The present study shows that leptin is detectable in
induced sputum of COPD patients. Leptin was
positively correlated with the inflammatory mar-
kers CRP and TNF-a in sputum. In COPD, chronic
airway inflammation is considered to be a hallmark,
characterized by profound neutrophilia and in-
creased sputum levels of IL-8, TNF-a and soluble
TNF-receptors, correlating with the degree of
airflow limitation.6,8 The finding that sputum leptin
was positively correlated with CRP and TNF-a in
these patients is an indication that leptin could be
involved in the local inflammatory response in
COPD.
To date, only few studies have addressed the
presence of leptin in the lung. Its presence,
together with the high concentrations of leptin
receptor2 suggests a specific local function of
leptin. Leptin was demonstrated to stimulate cell
proliferation in tracheal epithelial cells in vitro,
suggesting that leptin may function as a growth
factor helping to maintain the epithelial barrier.2 It
could also play a role in the local immune response,
as leptin receptors are found on neutrophils 9 and
T-cells.10
Structurally, leptin and leptin receptor are part
of the IL-6 super family,11,12 which is an important
inducer of acute-phase proteins like CRP. Systemi-
cally, CRP is involved in first line of innate host
defence, which includes activation of the classical
complement cascade and mediating phagocyto-
sis.13 TNF-a is a pro-inflammatory cytokine with
pleiotropic effects. TNF-a expression in the lung
has been described by several studies, being
produced locally mainly by activated macrophages
in response to inflammatory stimuli and functioning
as a chemoattractant for inflammatory cells.6,14
Although we did not further investigate this, we
hypothesize that the observed high correlation
between leptin and CRP in induced sputum may
indicate interplay between leptin and local inflam-
mation on the level of innate immune response.
CRP in sputum of chronic bronchitis patients has
been shown to have anti-bactericidal activities
in vitro.15 CRP is expressed in human respiratory
epithelial cells and in stimulated human alveolar
macrophages15,16 and mediates phagocytosis. On
the other hand, leptin-deficient mice have been
shown to have a reduced defence against bacteria,
which was associated with in vitro defective
alveolar phagocytosis. The addition of leptin has
been found to restore this defect.17 This may
suggest a co-dependence between leptin and CRP
in activated macrophages. This hypothesis should
be further investigated in future studies. The fact
that TNF-a in the lung is mainly produced by
activated macrophages, can explain the observed
correlations between the three markers.
The inverse correlation between sputum leptin
and plasma leptin found in the present study makes
it unlikely that the presence of leptin in sputum is
attributable to microvascular leakage from the
plasma leptin pool. As opposed to plasma leptin,
which is produced by fat cells and therefore
corrected for FM, leptin in sputum could be
synthesized in the lung itself. Fetal rat lung
fibroblasts, which are adipocyte-like cells, are
reported to secrete leptin.18 In addition, prelimin-
ary observations by Bruno et al. suggested an
increased expression of leptin in the submucosa of
bronchial biopsies of patients with COPD compared
to controls.10 Future research is needed to eluci-
date the origin of leptin in the lung.
Sputum induction with hypertonic saline may
hypothetically stimulate synthesis of airway inflam-
matory mediators. However, induced sputum
yielded the same cellular composition as sponta-
neous sputum in COPD patients.19 Moreover, soluble
inflammatory markers in induced sputum corre-
lated positively with those of lavage fluid.20 There-
fore, it is unlikely that sputum induction itself
stimulates airway inflammation.
Taken together, current data suggest that leptin
may be involved in the innate immune system of
the lungs in COPD. Future studies are clearly
necessary to elucidate the role of leptin in airways
of COPD patients.
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Figure 2 Correlation between leptin and TNF-a levels in
induced sputum (r ¼ 0:690; Po0:010).
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